Core Viewpoint - Omeros Corporation (OMER.US) experienced a significant stock surge of 150%, reaching a new high of $10.27, following the announcement of a final asset purchase and licensing agreement with Novo Nordisk for the candidate drug zaltenibart (OMS906) [1] Group 1: Agreement Details - The agreement grants Novo Nordisk exclusive global rights to develop and commercialize zaltenibart for all indications [1] - Omeros is eligible to receive an upfront payment of $340 million, along with milestone payments that could total up to $2.1 billion, including potential development and commercialization milestones [1] - Additionally, Omeros will receive tiered royalties based on net sales of the drug [1]